Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic agreement with the Allen Institute to investigate the relationship between tau protein and Alzheimer's disease using Nautilus' Iterative Mapping technology. The collaboration aims to identify and analyze tau proteoforms from human brain tissue to better understand their role in neurodegenerative conditions.
The partnership follows Nautilus' recent preprint demonstrating their single-molecule proteomics platform's capabilities in analyzing tau proteoforms with unprecedented resolution. The technology has shown promising results in studying brain samples from both cognitively normal and impaired Alzheimer's patients, validating the platform's accuracy, sensitivity, and reproducibility.
Nautilus Biotechnology (NASDAQ: NAUT) ha annunciato un accordo strategico con il Allen Institute per studiare la relazione tra la proteina tau e la malattia di Alzheimer utilizzando la tecnologia Iterative Mapping di Nautilus. La collaborazione mira a identificare e analizzare le proteoforme della tau nel tessuto cerebrale umano per comprendere meglio il loro ruolo nelle condizioni neurodegenerative.
La partnership segue la recente pubblicazione preliminare di Nautilus che dimostra le capacitĆ della loro piattaforma di proteomica a singola molecola nell'analisi delle proteoforme tau con una risoluzione senza precedenti. La tecnologia ha mostrato risultati promettenti nello studio di campioni cerebrali sia di pazienti cognitivamente normali sia di pazienti affetti da Alzheimer, confermando l'accuratezza, la sensibilitĆ e la riproducibilitĆ della piattaforma.
Nautilus Biotechnology (NASDAQ: NAUT) ha anunciado un acuerdo estratĆ©gico con el Allen Institute para investigar la relaciĆ³n entre la proteĆna tau y la enfermedad de Alzheimer utilizando la tecnologĆa Iterative Mapping de Nautilus. La colaboraciĆ³n tiene como objetivo identificar y analizar las proteoformas de tau en tejido cerebral humano para comprender mejor su papel en las enfermedades neurodegenerativas.
La asociaciĆ³n sigue a la reciente publicaciĆ³n preliminar de Nautilus que demuestra las capacidades de su plataforma de proteĆ³mica de molĆ©cula Ćŗnica para analizar las proteoformas tau con una resoluciĆ³n sin precedentes. La tecnologĆa ha mostrado resultados prometedores en el estudio de muestras cerebrales de pacientes tanto cognitivamente normales como afectados por Alzheimer, validando la precisiĆ³n, sensibilidad y reproducibilidad de la plataforma.
Nautilus Biotechnology (NASDAQ: NAUT)µē� Allen Instituteģ ģ ėµģ � ķģ½ģ� ģ²“ź²°ķģ¬ Nautilusģ� Iterative Mapping źø°ģ ģ� ģ¬ģ©ķ� ķģ� ėØė°±ģ§ź³¼ ģģø ķģ“ėØøė³ ź°ģ ź“ź³ė„¼ ģ”°ģ¬ķ� ģģ ģ ėė�. ģ“ė² ķė „ģ ģøź° ė� ģ”°ģ§ģģ ķģ� ķė”ķ ģ¤ķ¼ģ ģė³ķź³ ė¶ģķģ¬ ģ ź²½ķ“ķģ� ģ§ķģģ ź·� ģķ ģ� ė� ģ� ģ“ķ“ķµē ź²ģ ėŖ©ķė”� ķ©ėė�.
ģ“ė² ķķøėģģ Nautilusź° ģµź·¼ ė°ķķ� ėØģ¼ ė¶ģ ķė”ķ ģ¤ėƹģ¤ ķė«ķ¼ģ“ ķģ� ķė”ķ ģ¤ķ¼ģ ģ ė” ģµē ķ“ģėė” ė¶ģķ� ģ� ģģģ� ģ ģ¦ķ� ģė¹ ė ¼ė¬øģ� ģ“ģ“ ģ“ė£Øģ“ģ”ģµėė�. ģ� źø°ģ ģ ģøģ§ źø°ė„ģ� ģ ģģ� ķģģ ģģø ķģ“ėØ� ķģģ� ė� ģķ ģ°źµ¬ģģ ģ ė§ķ� ź²°ź³¼ė„� ė³“ģ¬ ķė«ķ¼ģ ģ ķģ�, ėƼź°ė� ė°� ģ¬ķģ±ģ ź²ģ¦ķģµėė�.
Nautilus Biotechnology (NASDAQ : NAUT) a annoncĆ© un accord stratĆ©gique avec le Allen Institute pour Ć©tudier la relation entre la protĆ©ine tau et la maladie d'Alzheimer en utilisant la technologie Iterative Mapping de Nautilus. Cette collaboration vise Ć identifier et analyser les protĆ©oformes de tau dans le tissu cĆ©rĆ©bral humain afin de mieux comprendre leur rĆ“le dans les maladies neurodĆ©gĆ©nĆ©ratives.
Ce partenariat fait suite Ć une prĆ©publication rĆ©cente de Nautilus dĆ©montrant les capacitĆ©s de leur plateforme de protĆ©omique Ć molĆ©cule unique Ć analyser les protĆ©oformes tau avec une rĆ©solution sans prĆ©cĆ©dent. La technologie a donnĆ© des rĆ©sultats prometteurs dans l'Ć©tude d'Ć©chantillons cĆ©rĆ©braux de patients cognitivement normaux et atteints d'Alzheimer, validant ainsi la prĆ©cision, la sensibilitĆ© et la reproductibilitĆ© de la plateforme.
Nautilus Biotechnology (NASDAQ: NAUT) hat eine strategische Vereinbarung mit dem Allen Institute bekanntgegeben, um die Beziehung zwischen Tau-Protein und Alzheimer-Krankheit mithilfe der Iterative Mapping-Technologie von Nautilus zu untersuchen. Die Zusammenarbeit zielt darauf ab, Tau-Proteoformen aus menschlichem Hirngewebe zu identifizieren und zu analysieren, um deren Rolle bei neurodegenerativen Erkrankungen besser zu verstehen.
Die Partnerschaft folgt auf eine kĆ¼rzlich verƶffentlichte Vorabversion von Nautilus, die die FƤhigkeiten ihrer EinzelmolekĆ¼l-Proteomik-Plattform zur Analyse von Tau-Proteoformen mit beispielloser Auflƶsung demonstriert. Die Technologie zeigte vielversprechende Ergebnisse bei der Untersuchung von Gehirnproben sowohl von kognitiv normalen als auch von Alzheimer-Patienten, was die Genauigkeit, SensitivitƤt und Reproduzierbarkeit der Plattform bestƤtigt.
- Partnership with prestigious Allen Institute validates Nautilus' single-molecule proteomics technology
- Technology demonstrates capability to analyze tau proteoforms at unprecedented resolution
- Platform shows promising potential for advancing Alzheimer's disease research and treatment
- Early-stage research with no immediate revenue impact
- No clear timeline for commercial applications or therapeutic developments
Insights
Nautilus's partnership with Allen Institute validates their single-molecule proteomics technology for Alzheimer's research, strengthening their competitive position.
This partnership between Nautilus Biotechnology and the Allen Institute represents a significant validation of Nautilus's Iterative Mapping technology in the competitive proteomics landscape. The collaboration specifically targets tau protein proteoforms in Alzheimer's diseaseāa crucial but poorly understood aspect of neurodegeneration. Tau phosphorylation patterns appear to play a critical role in disease progression, making this a high-value research target.
What makes this particularly notable is that Nautilus's single-molecule approach offers unprecedented resolution to identify and quantify specific tau proteoforms from human brain tissue. Traditional proteomics methods struggle with detecting subtle post-translational modifications and low-abundance protein variants that may be critical disease drivers. The company's recently published preprint demonstrates their platform's capability to achieve this granular level of protein analysis.
The technical differentiation here is substantialāNautilus describes their method as "an entirely new class of measurement" rather than an incremental improvement. Their platform's ability to interrogate millions to billions of individual protein molecules provides a fundamentally different approach to understanding protein biology at scale. The Allen Institute's engagement suggests the scientific community recognizes this technology's potential to overcome longstanding analytical barriers in neurodegenerative disease research.
From a competitive standpoint, this partnership strengthens Nautilus's position against other next-generation proteomics platforms by demonstrating real-world application in one of medicine's most challenging and commercially significant areas. Successful identification of novel tau biomarkers could potentially transform both diagnostic and therapeutic approaches to Alzheimer's disease.
ā� Allen Institute to employ Iterative Mapping, Nautilusā� single-molecule proteomics method, to investigate connection between tau protein and Alzheimerās disease
ā� Agreement links the organizationsā� next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease
SEATTLE, July 30, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or āNautilusā�), a company pioneering single-molecule proteome analysis, today announced they have entered into an agreement with the focused on investigating the connection between the tau protein and neurodegenerative conditions such as Alzheimerās disease. This further validates the importance and potential of novel single-molecule proteomic data like that shared in Nautilusā� recent .
While little is currently known about tau proteoforms ā� the many functional variants of tau ā� and how they influence Alzheimerās disease progression, recent studies suggest that the order, timing, and extent of tau phosphorylation play critical roles in the disease. As part of this agreement, Nautilus and the Allen Institute aim to identify novel tau proteoforms from human brain tissue, quantify their prevalence, and characterize patterns of phosphorylation that may help predict the course of the disease.
āWe are pleased to partner with the Allen Institute to answer highly impactful questions about the role of tau proteoforms in Alzheimerās disease and to further demonstrate the critical role that single-molecule protein analysis may play in advancing the development of new diagnostics and treatments,ā� said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. āOur Iterative Mapping approach is generating excitement from the wider scientific community which sees it as an entirely new class of measurementāa fundamentally different way to understand biologyāand we are thrilled to continue pushing the frontiers of proteomics with pioneers like the researchers at the Allen Institute.ā�
Nautilusā� preprint, titled āDevelopment of a method for large-scale single-molecule analysis of tau proteoforms,ā� details the real-world capabilities of its proteomics platform to achieve an unprecedented level of resolution, providing actionable biological insights from studying brain samples of cognitively normal and impaired patients with Alzheimerās. The companyās studies present initial validation of the accuracy, sensitivity, dynamic range, and reproducibility of Iterative Mapping for interrogating millions to billions of single-protein molecules in a scalable, adaptable manner.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilusā� mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .
About the Allen InstituteĀ
The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary, the late Paul G. Allen. The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide. The Institute is a recognized leader in large-scale research with a commitment to an open science model. Its research institutes and programs include the Allen Institute for Brain Science, the Allen Institute for Cell Science, the Allen Institute for Immunology, and the Allen Institute for Neural Dynamics. In 2016, the Allen Institute expanded its reach with the launch of The Paul G. Allen Frontiers Group, which identifies pioneers with new ideas to expand the boundaries of knowledge and make the world better. For more information, visitĀ
Media Contact
[email protected]
Investor Contact
[email protected]
FAQ
What is the purpose of Nautilus Biotechnology's agreement with the Allen Institute?
How does Nautilus Biotechnology's (NAUT) Iterative Mapping technology work in Alzheimer's research?
What are the key findings from Nautilus Biotechnology's recent preprint study?
How might this partnership impact Alzheimer's disease research?
